| 王慜杰,韩彬彬,李学祥.乳腺癌患者血清Her-2/neu蛋白的临床意义[J].中国肿瘤,2013,22(4):295-298. |
| 乳腺癌患者血清Her-2/neu蛋白的临床意义 |
| Clinical Significance of Serum Her-2/neu Protein in Patients with Breast Cancer |
| 投稿时间：2012-11-20 |
| DOI：10.11735/j.issn.1004-0242.2013.04.A2012366 |
|
 |
| 中文关键词: 乳腺癌 人类表皮生长因子受体-2 化学发光法 临床价值 |
| 英文关键词:breast cancer serum Her-2/neu chemiluminescence immunoassay clinical value |
| 基金项目: |
|
| 摘要点击次数: 4052 |
| 全文下载次数: 1938 |
| 中文摘要: |
| 摘 要：［目的］探讨血清Her-2/neu蛋白在乳腺癌患者诊疗中的临床意义。［方法］应用化学发光法(chemiluminescence immunoassay，CLIA)对60例健康人、100例其他肿瘤患者和195例乳腺癌患者样本进行Her-2/neu蛋白检测。［结果］健康对照组、其他肿瘤对照组和乳腺癌组血清Her-2/neu浓度分别为10.3±1.7ng/ml、10.9±2.6ng/ml和23.7±38.8ng/ml，乳腺癌组浓度明显高于健康对照组（P=0.003）和其他肿瘤组（P=0.005）。Ⅰ~Ⅱ期乳腺癌血清Her-2/neu浓度明显低于Ⅲ~Ⅳ期，差异有统计学意义（P=0.001）。乳腺癌Her-2阴性、+、++和+++ 4组患者血清Her-2/neu蛋白浓度分别为32.3±56.2ng/ml、27.9±31.4ng/ml、17.7±29.2ng/ml和23.1±39.6ng/ml；血清Her-2/neu蛋白阳性率分别为26.67%、33.33%、11.11%和15.38%。转移性乳腺癌患者血清Her-2/neu检测结果与临床状态总体符合率为82.98%（39/47）。［结论］ 血清Her-2/neu蛋白水平与乳腺癌患者临床分期相关，化学发光法检测血清Her-2/neu蛋白在乳腺癌临床诊疗中有重要应用价值。 |
| 英文摘要: |
| Abstract:［Purpose］ To investigate the clinical sinificance of serum Her-2/neu protein in the diagnosis and treatment for patients with breast cancer. ［Methods］ Chemiluminescence immunoassay(CLIA) was used to detect serum Her-2/neu protein concentration from 60 cases of healthy control，195 cases of breast cancer and 100 cases of other cancers.［Results］ The serum Her-2/neu concentration in breast cancer group (23.7±38.8ng/ml) was significantly higher than that in healthy control group(10.3±1.7ng/ml)(P=0.003) and other cancers group(10.9±2.6ng/ml)(P=0.005). The serum Her-2/neu concentration in patients with breast cancer (stage Ⅰ~Ⅱ) was significantly lower than that with stage Ⅲ~Ⅳ， with significant difference(P=0.001). Based on the Her-2 immunohistochemical results，the breast cancer patients were divided into 4 groups: negative，+，++，+++. The serum Her-2/neu concentration were 32.3±56.2ng/ml，27.9±31.4ng/ml，17.7±29.2ng/ml and 23.1±39.6ng/ml respectively; and the positive rate of serum Her-2/neu protein was 26.67%，33.33%，11.11% and 15.38% respectively. The level of serum Her-2/neu was 82.98% accorded with clinical status in patients with metastatic breast cancer.［Conclusion］ Serum Her-2/neu level in breast cancer patients is associated with clinical stage，and the CLIA Her-2/neu assay plays an important application value in diagnosis，prognosis and treatment for breast cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |